Home|Journals|Articles by Year

Directory for Medical Articles
 

Case Report



Medical Treatment with Albendazole of A Patient with Hepatic Cystic Echinococcosis who Should have Undergone Elective Surgery in the Context of Pandemic of COVID-19

Leonardo Javier Uchiumi, Mariela Denis Bezic.


Abstract

Cystic echinococcosis (CE) is worldwide endemic parasitic zoonosis caused by tapeworm Echinococcus granulosus. In human, liver is most common organ affected up to 85%. Informal Working Group on Echinococcosis (IWGE) of World Health Organization (WHO) published a standard classification of the cysts based on ultrasound (1) and a consensus in 2010 suggesting treating with albendazol as first choice of treatment in uncomplicated CE1 and CE3a up to 5 cm (2). In the context of pandemic of COVID-19, patients who requires elective percutaneous or surgical treatment for symptomatic non-complicated hepatic CE must be delayed or suspended because this disease is not life threatening unless it's complicated and by the shortness of bed and the risk of intra-hospital COVID-19 infection. The aim of this case report is to describe the follow up of a patient with hepatic cystic echinococcosis who should have undergone elective precutaneous or surgical treatment, treated with albendazole in the context of a pandemic COVID-19.

Key words: Cystic echinococcosis, liver, albendazole, pandemic COVID-19






Full-text options


Share this Article



Online Article Submission
• ejmanager.com







eJManager.com
Review(er)s Central
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.